ReviewHealth economics review2021
Cost analysis of chronic obstructive pulmonary disease (COPD): a systematic review.
Review in Health economics review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06308302 (Comparative Effects of Inspiratory Muscle Training vs Expiratory Muscle Training Along With Aerobic Interval Training on Functional Performance and Fatigue Level in COPD Patients), which is not on this map. Cited by 74 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effects of Inspiratory Muscle Training vs Expiratory Muscle Training Along With Aerobic Interval Training on Functional Performance and Fatigue Level in COPD Patients
Who cites it
74 citing papers in PubMed, 5 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- COPD-patients' perspective on adherence to therapy and its integration into a systematic literature review.BMC pulmonary medicine · 2026Pooled it
- Global Economic and Social Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review (2020-2024).International journal of chronic obstructive pulmonary disease · 2026Pooled it
- The patient-level economic burden of COPD in China: a systematic review of determinants and consequences.Frontiers in public health · 2026Pooled it
- Cost-effectiveness of home care compared to hospital care in patients with chronic obstructive pulmonary disease (COPD): a systematic review.Frontiers in medicine · 2024Pooled it
- A Systematic Review of the Effectiveness of Interventions to Promote Referral; Adherence; and Uptake of Pulmonary Rehabilitation for Patients with Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023Pooled it
- Identifying patients with mild-to-moderate COPD who require intensified initial treatment to control annualized clinically important deterioration.NPJ primary care respiratory medicine · 2026Trial
- Bisoprolol for patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS RCT.Health technology assessment (Winchester, England) · 2025Trial
- Trial
- The Financial Burden of Prescribed Medications in COPD.CHEST pulmonary · 2026Article
- Low-density lipoprotein cholesterol and risk of COPD: a Mendelian randomization study.Scientific reports · 2026Article
- Integrated Network Pharmacology and Molecular Docking Uncover Multi-Target Actions ofInternational journal of molecular sciences · 2026Article
- Characterization of Patients with COPD and GOLD E Classification in the United States.International journal of chronic obstructive pulmonary disease · 2026Article
- Effects of long-term, home-based, virtual cycling after COPD exacerbation - results from the randomised controlled COPDtoParis trial.European clinical respiratory journal · 2026Article
- The contributions of active and passive smoking to COPD-related mortality and DALYs in the context of COVID-19: Global Burden 2019-2021.Tobacco induced diseases · 2026Article
- Integrating Disease Burden and Cost-Effectiveness for Value-Based Prioritisation of COPD Interventions: A Narrative Review.International journal of chronic obstructive pulmonary disease · 2026Review
- Identifying the Challenges in Self-Management and Preferences for Digital Health Technologies Use Among COPD Patients Based on the CeHRes Roadmap: A Formative Qualitative Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Psychometric testing of the 20-item Self-Management Assessment Scale in people with chronic obstructive pulmonary disease.Scientific reports · 2025Article
- Dyspnea in Chronic Obstructive Pulmonary Disease: Expert Assessment of Management in Clinical Practice.Pulmonary therapy · 2025Article
- Association of Carbohydrate Antigen 125 Levels and Right Ventricular Dysfunction in Patients With Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study.Health science reports · 2025Article
- Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic Obstructive Pulmonary Disease (COPD) is a treatable disease with a high prevalence, and high morbidity associated with significant socioeconomic costs.
objectiveTo carry out a systematic review of the literature to analyze the main cost studies associated with COPD, in order to determine the main factors that influence the costs of the disease.
methodsSearches were conducted in PubMed, SCOPUS and Web of Science databases for cost studies on COPD published in English, between the years 2015 and 2020. The search terms were "COPD" OR "pulmonary disease, chronic obstructive", "cost*" OR "cost of illness", "economic impact" AND "burden of disease". The inclusion criteria included the identification of reported cost of the disease, economic burden, medical care expenses or use resources for COPD, the methodology used, data sources, and variables studied.
results18 publications were analyzed: 17 included direct health costs, 6 included direct non-medical costs, 12 analyzed indirect costs and two reported intangible costs. Most of the studies reported data for developed and European countries, with direct costs being the most studied. Trends were observed in multiple studies of direct and healthcare costs for European countries measured by patient and year, where the higher costs were associated with more severe COPD and a frequent history of exacerbations. The highest costs reported corresponded to hospitalizations and the associated pharmacological treatment. The importance of the loss of productivity and premature retirement within the profile of the COPD patient was also highlighted as the main generator of indirect costs of the disease.
conclusionCOPD generates substantial costs for the health system, mainly related to moderate to severe stages and the exacerbations and complications entailed. It is important to strengthen health systems with monitoring, evaluation and health education models that allow these patients to remain stable to avoid decompensation and subsequent hospitalizations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.